STAT

STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trialWorldPing

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

Related news